MAR 0 6 2007 & INJETHE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Confirmation No.: 6968

Li et al.

Art Unit: 1643

Appl. No. 09/720,086

Examiner: Harris, A. M.

§ 371 Date: July 23, 2001

Atty.Docket:0609.4560002/KRM/DJN

For:

De Novo DNA Cytosine Methyltransferase Genes,

Polypeptides and Uses Thereof

Supplemental Amendment and Reply Under 37 C.F.R. § 1.116

Mail Stop: AF

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Further to the Amendment and Reply after final filed December 6, 2006, and in reply to the Advisory Action dated February 27, 2007, Applicants submit the following Amendment and Remarks. This Reply is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
 - in ascending order;
 - with status identifiers; and
 - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.